KDR and neoplasm: To study the influence of the VEGFR-2 DNA dose and vaccination schedule on the induction of tumor antigen specific cytotoxic T-lymphocytes we incubated splenocytes with tumor cells expressing human VEGFR-2 at an effector:target ratio of 20:1.